Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 19/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 7/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 7/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13503323 | 1.00 | CNR2 (0.64) | CNR2CYP2C19CYP2C9CYP3A4CYP1A2 | |
| SCHEMBL13503331 | 0.91 | CNR2 (0.64) | CNR2CYP2C19CYP2C9CYP3A4CYP1A2 | |
| SCHEMBL13503322 | 0.91 | CNR2 (0.64) | CNR2CYP2C19CYP2C9CYP3A4CYP1A2 | |
| SCHEMBL13503353 | 0.90 | CNR2 (0.77) | CNR2CYP2C19CYP2C9CYP3A4CYP1A2 | |
| SCHEMBL13503321 | 0.90 | CNR2 (0.77) | CNR2CYP2C19CYP2C9CYP3A4CYP1A2 | |
| SCHEMBL14319075 | 0.90 | CNR2 (0.53) | CNR2CYP2C19CYP2C9CYP3A4CYP1A2 | |
| SCHEMBL3380567 | 0.87 | CNR2 (0.80) | CNR2CYP2C19CYP2C9CYP3A4CYP1A2 | |
| SCHEMBL3379860 | 0.87 | CNR2 (0.80) | CNR2CYP2C19CYP2C9CYP3A4CYP1A2 | |
| SCHEMBL3382212 | 0.87 | CNR2 (0.79) | CNR2CYP2C19CYP2C9CYP3A4CYP1A2 | |
| SCHEMBL13503315 | 0.86 | CNR2 (0.81) | CNR2CYP2C19CYP2C9CYP3A4CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100041654-A1 | Pyrimidine Derivatives And Their Use As CB2 Modulators | EATHERTON ANDREW JOHN | 2010-02-18 | — | — | US | disclosed |
| US-20100041654-A1 | Pyrimidine Derivatives And Their Use As CB2 Modulators | EATHERTON ANDREW JOHN | 2010-02-18 | — | — | US | disclosed |
| US-7635701-B2 | Pyrimidine derivatives and their use as CB2 modulators | GLAXO GROUP LIMITED (GB) | 2009-12-22 | — | — | US | disclosed |
| US-7635701-B2 | Pyrimidine derivatives and their use as CB2 modulators | GLAXO GROUP LIMITED (GB) | 2009-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041654-A1 | Pyrimidine Derivatives And Their Use As CB2 Modulators | CNR2, CNR1, P2RY2 | CNR2 1/4885CYP2C19 641/4885CYP2C9 969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.